Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
ADIAL PHARMACEUTICALS, INC. shareholders approved Approval of an amendment to the Company’s 2017 Equity Incentive Plan to increase the number of shares of common stock authorized for grant under the plan from 380,000 to 500,000 at the 2023-11-02 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-11-02
Exact text from the filing
The stockholders approved the amendment (Amendment No. 5) to the Company’s 2017 Equity Incentive Plan to increase the number of shares of common stock authorized for grant under the 2017 Equity Incentive Plan from 380,000 to 500,000 based on the votes listed below: Votes For Votes Against Abstentions Broker Non-Votes 244,858 113,670 1,097 197,676
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
ADIAL PHARMACEUTICALS, INC. shareholders approved Election of Directors at the 2023-11-02 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-11-02
Exact text from the filing
On November 2, 2023, at the Annual Meeting, the Company’s stockholders voted on the following three (3) proposals and votes were cast as described below.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
ADIAL PHARMACEUTICALS, INC. shareholders approved Ratification of the appointment of Marcum, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2023-11-02 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-11-02
Exact text from the filing
The stockholders ratified and approved the appointment of Marcum, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023, based on the votes listed below: Votes For Votes Against Abstentions 542,258 3,868 11,175
View on SEC.gov